![]() | |
Clinical data | |
---|---|
Trade names | Duratocin, Pabal, Lonactene, others |
Other names | (2-O-Methyltyrosine)deamino-1-carbaoxytocin; Deamino-2-O-methyltyrosine-1-carbaoxytocin; 1-Butanoic acid-2-(O-methy-L-tyrosine)-1-carbaoxytocin; 1-butyric acid-2-[3-(4-methoxyphenyl)-L-alanine]oxytocin |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Routes of administration | Intravenous, intramuscular |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 80% (IM) |
Elimination half-life | 85–100 minutes[1] |
Identifiers | |
| |
Chemical and physical data | |
Formula | C45H69N11O12S |
Molar mass | 988.17 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Carbetocin, sold under the brand names Pabal among others, is a medication used to prevent excessive bleeding after childbirth, particularly following Cesarean section.[3] It appears to work as well as oxytocin.[4] Due to it being less economical than other options, use is not recommended by NHS Scotland.[3] It is given by injection into a vein or muscle.[4]
Side effects differ little from that of no treatment or placebo.[4] Use is not recommended in people with epilepsy or eclampsia.[3] Carbetocin is manufactured long acting form of oxytocin.[4] It works by activating the oxytocin receptor which causes the uterus to contract.[5][4]
Carbetocin was first described in 1974.[6] It was approved for medical use in Canada and the United Kingdom in 1997.[4] It is on the World Health Organization's List of Essential Medicines.[7] In the United Kingdom it costs the NHS £18 a dose as of 2018.[3] Globally prices range from £8 to £40.[4] It is not available in the United States or Japan.[8][4]
References
edit- ^ Idan Shalev; Richard Paul Ebstein (11 February 2015). Social Hormones and Human Behavior: What Do We Know and Where Do We Go from Here. Frontiers Media SA. pp. 51–. ISBN 978-2-88919-407-0.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 10 September 2020.
- ^ a b c d British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 804. ISBN 9780857113382.
- ^ a b c d e f g h "PROPOSAL FOR INCLUSION OF CARBETOCIN IN THE WHO LIST OF ESSENTIAL MEDICINES" (PDF). WHO. Retrieved 12 November 2019.
- ^ I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 65–. ISBN 978-94-011-4439-1.
- ^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 214–. ISBN 978-1-4757-2085-3.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ "Carbetocin Drug Information, Professional". Drugs.com. Retrieved 26 December 2020.